Meeting Modern Data Integrity and Compliance Requirements
White Paper Sep 01, 2017
The FDA was perhaps understating a point when it said in its April 2016 Draft Guidance: Data Integrity and Compliance with cGMP1 that the increasing number of data integrity-related cGMP violations identified during its inspections was ‘troubling’. In fact, 21 out of 28 warning letters issued by the agency between January 2015 and May 2016 involved data integrity issues in drug manufacturing.
Ultimately, whether you are a drug manufacturer, clinical research organisation (CRO) or pharmaceutical R&D company, the accuracy and completeness of data is critical for safe product development, and any breach of data integrity could have serious implications for human health.
Download this whitepaper to learn more about meeting modern data integrity and compliance requirements.
Learn more about modern data integrity and compliance requirements in this free to attend webinar.
Related White Papers
How to Identify Low-Abundance Modified Peptides with Proteomics Mass SpectrometryWhite Paper
We present a new simplicity-focused analytics methodology, called Sorcerer Score™ that allows low-abundance, modified peptides (LAMPs) to be rigorously identified within a hypothesis-driven framework based on high-accuracy precursor and fragment mass data. Accurate peptide ID is fundamental to accurate protein quantitation and post-translational modification (PTM) analysis.READ MORE
Selecting the Best Microfluidics Device Material for Your In Vitro DiagnosticWhite Paper
Microfluidic flow cell approach is examined, addressing the advantages and disadvantages of using this when automating and miniaturizing in vitro diagnostics.READ MORE
Big Data Lipidomics for Lipid Biomarker Identification and Drug DiscoveryWhite Paper
Data analysis process aiming at the identification of lipid biomarkers and the
evaluations of their performance.